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ABSTRACT 
This is a retrospective study done at the Mycetoma 
Research Centre at Suba University Hospital from January 1994 to 
December 2003 on 3222 mycetoma patients to study the recurrence 
of mycetoma following medicosurgical approach. The male to 
female ratio is 3 : 1 and the age commonly affected ranged 
between 11 to 30 years. Eumycetomal represent 81.1% and 
actinomycetoma 19.9%. Mycetoma affects mainly students of farm 
workers. Medical treatment was given to all patients and surgery 
undertaken for 2762.   
The recurrence rate is 24%. The recurrence rate among 
females is 17.9% and in males it is 26%. In eumycetoma the rate of 
recurrence is 19.9% and in actinomycetoma  42.9%. The recurrence 
rate in patients with a duration of less than 1 year is 10.7%, while 
in those of duration of more than 10 years it is 40.5%. The back has 
the highest rate of recurrence (40%), while the hand is the least site 
(14%). In the absence of sinuses the recurrence rate is 9.6%. When 
the sinuses are active the recurrence rate is 25.8%. In the presence 
of enlarged regional lymph glands the recurrence rate is 53.2% and 
in their absence it is 15.9%. With bone involvement the rate is 
53.2% and in their absence it is 15.9%. With bone involvement the 
rate of recurrence is 49.9%, with only soft tissue mass it 22.5%, 
while when the X-ray is normal  it is 15.8%. Only 17.2% of patients 
with previous surgery received medical therapy for mycetoma, 
and 52.2% had been done under local anaesthesia, 39.9% under 
 general anaesthesia, and 7% under spinal anaesthesia. 49.1% are 
cured during the first year, 11.2% needed treatment for 4 years. 
The commonest period of recurrence is the second and third year.   
One can conclude that medicosurgical approach had 
confirmed it efficiency in reducing the recurrence rate of 
mycetoma and no place for at least major amputation. Close 
follow-up in mycetoma centers is highly recommended.    
  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  اﻷﻃﺮوﺣﺔﻣﻠﺨﺺ 
 ﺠﺎﻤﻌﺔ –ﺍﻟﻤﺎﻴﺴﺘﻭﻤﺎ ﺒﻤﺴﺘﺸﻔﻰ ﺴﻭﺒﺎ ﺍﻟﺠﺎﻤﻌﻲﺃﺠﺭﻴﺕ ﻫﺫﻩ ﺍﻟﺩﺭﺍﺴﺔ ﺍﻟﺭﺠﻌﻴﺔ ﻓﻲ ﻤﺭﻜﺯ ﺃﺒﺤﺎﺙ 
 ﻤﺭﻴﺽ 2223 ﻭﻗﺩ ﺸﻤﻠﺕ ،3002ﻡ ﻭﺤﺘﻰ ﺩﻴﺴﻤﺒﺭ 4991ﻓﻲ ﺍﻟﻔﺘﺭﺓ ﻤﻥ ﻴﻨﺎﻴﺭ . ﺍﻟﺨﺭﻁﻭﻡ
ﺘﻬﺩﻑ ﻫﺫﻩ ﺍﻟﺩﺭﺍﺴﺔ ﻟﺘﺤﺩﻴﺩ ﻋﻭﺍﻤل ﺭﺠﻭﻉ ﺍﻟﻤﺭﺽ ﻋﻠﻰ ﻀﻭﺀ ﺍﻟﻌﻼﺝ ﺍﻟﺩﻭﺍﺌﻲ ﻭ . ﺒﺎﻟﻤﺎﻴﺴﺘﻭﻤﺎ
 ﺴﻨﺔ ﺍﻟﻰ 11 ﻭﺍﻜﺜﺭ ﺍﻷﻋﻤﺎﺭ ﺃﺼﺎﺒﺔ ﻤﺎﺒﻴﻥ 3:1ﻨﺴﺒﺔ ﺍﻟﺫﻜﻭﺭ ﻟﻸﻨﺎﺙ ﻜﺎﻨﺕ  . ﻭﺝﺍﻟﻤﺯﺩﺍﻟﺠﺭﺍﺤﻲ 
ﻤﻌﻅﻡ . %9.91ﻤﺎ ﻤﺜﻠﺕ ﺍﻷﻜﺘﺎﻴﻨﻭﻤﺎﻴﺴﺘﻭﻤﺎ ﺒﻴﻨ% 1.18ﻨﺴﺒﺔ ﺍﻹﺼﺎﺒﺔ ﺒﺎﻟﻴﻭﻤﺎﻴﺴﺘﻭﻤﺎ .  ﺴﻨﺔ 03
 ﻜل ﺍﻟﻤﺭﻀﻰ ﻋﻼﺠﺎﹰ ﺩﻭﺍﺌﻴﺎﹰ ﻰ ﻭﻗﺩ ﺘﻠﻘﻥ ﻓﺌﺎﺕ ﻁﻼﺏ ﺍﻟﻤﺩﺍﺭﺱ ﻭ ﺍﻟﻤﺯﺍﺭﻋﻴﻥﺍﻟﻤﺼﺎﺒﻴﻥ ﻜﺎﻨﻭﺍ ﻤ
  .  ﻋﻤﻠﻴﺔ 2672ﺒﻴﻨﻤﺎ ﺃﺠﺭﻴﺕ ﺤﻭﺍﻟﻲ 
  
ﻭﻓﻲ % 9.71، ﺤﻴﺙ ﻜﺎﻨﺕ ﻨﺴﺒﺔ ﺭﺠﻭﻉ ﺍﻟﻤﺭﺽ ﻓﻲ ﺍﻷﻨﺎﺙ %42ﻨﺴﺒﺔ ﺭﺠﻭﻉ ﺍﻟﻤﺭﺽ ﻜﺎﻨﺕ 
%. 9.24ﻭﻓﻲ ﺍﻷﻜﺘﺎﻴﻨﻭﻤﺎﻴﺴﺘﻭﻤﺎ % 9.91ﻨﺴﺒﺔ ﺭﺠﻭﻉ ﺍﻟﻴﻭﻤﺎﻴﺴﺘﻭﻤﺎ ﻜﺎﻨﺕ % . 62ﺍﻟﺫﻜﻭﺭ 
% 5.04ﻭﻗﺩ ﺃﺭﺘﻔﻌﺕ ﻫﺫﻩ ﺍﻟﻨﺴﺒﺔ ﺍﻟﻰ % 7.01ﻨﺴﺒﺔ ﺭﺠﻭﻉ ﺍﻟﻤﺭﺽ ﻓﻲ ﻓﺘﺭﺓ ﺃﻗل ﻤﻥ ﺴﻨﺔ ﻜﺎﻨﺕ 
ﻤﻨﻁﻘﺔ ﺍﻟﻅﻬﺭ ﻜﺎﻨﺕ ﻤﻥ ﺍﻜﺜﺭ ﺍﻟﻤﻭﺍﻀﻊ ﻓﻲ .  ﺴﻨﻭﺍﺕ01ﺽ ﺍﻜﺜﺭ ﻤﻥ ﻋﻨﺩﻤﺎ ﻜﺎﻨﺕ ﻤﺩﺓ ﺍﻟﻤﺭ
ﻓﻲ ﻋﺩﻡ ﻭﺠﻭﺩ ﺍﻟﺠﻴﻭﺏ %. 41ﺍﻟﺠﺴﻡ ﺭﺠﻭﻋﺎﹰ ﻟﻠﻤﺭﺽ  ﺒﻴﻨﻤﺎ ﺍﻷﻴﺩﻱ ﺍﻗﻠﻬﺎ ﺭﺠﻭﻋﺎﹰ ﻭﻤﺜﻠﺕ ﻨﺴﺒﺔ 
، ﻭﻋﻨﺩﻫﺎ ﻜﺎﻨﺕ ﻫﺫﻩ ﺍﻟﺠﻴﻭﺏ ﻨﺸﻁﺔ ﻜﺎﻨﺕ ﻨﺴﺒﺔ ﺍﻟﺭﺠﻭﻉ %6.9ﻜﺎﻥ ﺭﺠﻭﻉ ﺍﻟﻤﺭﺽ ﺒﻨﺴﺒﺔ 
ﺒﻴﻨﻤﺎ % 9.51ﺤﺕ ﻨﺴﺒﺔ ﺍﻟﺭﺠﻭﻉ ﻓﻲ ﺤﺎﻟﺔ ﻋﺩﻡ ﻭﺠﻭﺩ ﻏﺩﺩ ﻟﻴﻤﻔﺎﻭﻴﺔ ﻤﺘﻀﺨﻤﺔ ﺍﺼﺒ%. 8.52
ﻜﺎﻨﺕ ﻨﺴﺒﺔ ﺭﺠﻭﻉ . ﻤﻊ ﻭﺠﻭﺩ ﻏﺩﺩ ﻟﻴﻤﻔﺎﻭﻴﺔ ﻤﺘﻀﺨﻤﺔ % 2.35ﺃﺭﺘﻔﻌﺕ ﻫﺫﻩ ﺍﻟﻨﺴﺒﺔ ﺍﻟﻰ 
ﻭﻋﻨﺩ ﻅﻬﻭﺭ ﺼﻭﺭﺓ ﺍﻷﺸﻌﺔ ﺒﻤﻅﻬﺭ ﻋﺎﺩﻱ % 9.94ﺍﻟﻤﺎﻴﺴﺘﻭﻤﺎ ﻓﻲ ﺤﺎل ﻭﺼﻠﺕ ﺍﻟﻰ ﺍﻟﻌﻅﻡ 
% 2.11ﺒﻴﻨﻤﺎ %  1.94ﺍﻟﻤﺭﻀﻰ ﺍﻟﺫﻴﻥ ﺘﻡ ﺸﻔﺎﺅﻫﻡ ﺨﻼل ﺴﻨﺔ %. 8.51ﻜﺎﻨﺕ ﻨﺴﺒﺔ ﺍﻟﺭﺠﻭﻉ 
ﺍﻜﺜﺭ ﻓﺘﺭﺍﺕ ﺭﺠﻭﻉ ﺍﻟﻤﺎﻴﺴﺘﻭﻤﺎ ﻜﺎﻨﺕ ﻓﻲ . ﻌﻼﺝ ﻟﻤﺩﺓ ﻋﻼﺝ ﺍﻜﺜﺭ ﻤﻥ ﺜﻼﺜﺔ ﺴﻨﻭﺍﺕﺍﺤﺘﺎﺠﻭﺍ ﻟ
  . ﺍﻟﺴﻨﺔ ﺍﻟﺜﺎﻨﻴﺔ ﻭ ﺍﻟﺜﺎﻟﺜﺔ ﺒﻌﺩ ﺍﻟﺸﻔﺎﺀ
ﻟﻘﺩ ﺨﻠﺼﺕ ﻫﺫﻩ ﺍﻟﺩﺭﺍﺴﺔ ﺇﻟﻰ ﺃﻥ ﺍﻟﻌﻼﺝ ﺍﻟﺩﻭﺍﺌﻲ ﻭ ﺍﻟﺠﺭﺍﺤﻲ ﺍﻟﻤﺯﺩﻭﺝ ﺫﻭ ﻓﻌﺎﻟﻴﺔ ﻋﺎﻟﻴﺔ ﻭﺒﺫﻟﻙ 
  . ﻴﻤﻜﻥ ﺘﺠﻨﺏ ﺍﻟﺒﺘﺭ ﻓﻲ ﻤﺭﻀﻰ ﺍﻟﻤﺎﻴﺴﺘﻭﻤﺎ
  . ﻼﺝ ﻤﺭﻀﻰ ﺍﻟﻤﺎﻴﺴﺘﻭﻤﺎ ﻓﻲ ﻤﺭﺍﻜﺯ ﺨﺎﺼﺔ ﺒﻬﻡﺃﺨﻴﺭﺍﹰ ﻨﻭﺼﻲ ﺒﺄﻥ ﺘﺘﻡ ﻤﺘﺎﺒﻌﺔ ﻋ
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INTRODUCTION AND LITERATURE REVIEW 
 
Mycetoma is a chronic inflammatory condition of tropical and 
subtropical regions.  It is commoner in males, especially those in their 
third and fourth decades who work in the land.  The clinical triad of 
painless swelling, sinuses and grains usually leads to diagnosis; the 
disease is commonly painless. Treatment is by extensive surgical 
excision of affected areas and may be amputation of the affected part. 
Recurrence is common, rates ranging from 20 to 90%.  Medical 
treatment may be used on its own or as an adjunct to surgery.  
Although such therapy may cure over half of those with 
actinomycetoma (caused by bacteria, mainly aerobic actionmycetes), 
those affected by eumycetoma (caused by fungi) have a poorer 
prognosis and may require many years of drug therapy (1). 
There are no early record  of mycetoma, but by the year 1712 the 
condition had became sufficiently  known for Kaempfer to give the 
earliest recorded reference  to it as a recognizable entity(2). It was first 
described by Gill of madura in South India in 1842, hence the name 
“madura foot”(1). In 1860 Carter introduced the name Mycetoma 
  2
“fungal tumour” to indicate the origin of the disease(1). Boyce and 
Surveyor in 1894 proved that, black and yellow grains were caused by 
different organisms.  In 1918,   Archibald and Chalmers from the 
Sudan defined and classified maduramycosis.   Then followed a period 
in the first half of the last century when many saphrophytes and 
microbic variants were isolated and presented as the cause of 
mycetomatous lesions.  Since then chiefly through the work of Juan 
MacKinnon of Uruguay and the scientists of the Pasteur institute of 
Paris and Dakar, the Taxonomy of the causal fungi and actinomycetes 
has been considerably clarified (2). 
The definition  of mycetoma was given by Archibald and Chalmers in 
1918 as follow: All growth and granulations producing enlargement, 
deformity and destruction in any part of man, brought about by the 
invasion of the affected area by certain species of fungi belonging to 
different genera which gave rise to variously coloured and shaped 
bodies called “ grains”, which are formed of hyphae with or without 
chlamidospors, and are found either embedded in the pathological 
tissue forming the growth and granulations or escaping freely in the 
discharge from diseased area” (3).  
  3
Aetiology of mycetoma: 
Mycetoma can be caused by true fungi (eumycetoma) or aerobic 
actinomycetes which are higher filamentous bacteria 
(actinomycetoma). A number of organisms can cause mycetoma and 
about eighteen species of eumycetes and actinomycetes have been 
isolated from cases all over the world. 
Eumycetoma can be caused by various fungi which produce grains of 
different sizes, colours and consistency, depending on the causative 
organisms. The most common ones that cause black grains 
eumycetoma included Madurella mycetomatis, Madurella grisea 
Leptosphaeria senegalensis, Pyrenochaeta romeroi, Phialophora jeanselmi and 
Curvularia lunata. Their grains are usually big, approximately 1mm in 
diameter and hard.  Other eumycetes, like Pesudoallescheria  boydi and 
Aspergilus nidulans, produce big white grains.  The grains of the latter 
are soft, whereas Neotestudina rosatii produce hard brown- white grains 
(Mahgoub, 1999).  In 1973 Mahgoub had reported a case of green grain 
eumycetoma due to Aspergillus flavus (5). 
Actinomycetoma are mainly caused by aerobic actinomycetes which 
include Streptomyces somaliensis, that produces small, hard, dirty yellow 
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grains, Actinomadura madurae produces big, soft white grains.  A. 
pelletieri produce tiny, hard red grains and Nocardia species has small, 
beige-yellow or orange grains). The later include N. brasiliensis, N. 
asteroids, and N. otitidis cavarium which was previously know as          
N. caviae(4) . 
Epidemiology: 
The incidence and aetiological agents of mycetoma whether fungi or 
actionmycetes show distinct geographical differences.  The disease 
occurs in many parts of the world but more commonly in tropical and 
subtropical countries of Africa, the Middle East and other parts of Asia 
and South America. There is a mycetoma belt, which lies, between 15°S 
and 30°N of the equator where there is a higher incidence of savannah 
region than desert or tropical forests.  In this region most of the rain 
falls during a season lasting 3-4months. 
The remaining 8-9 months are hot and dry which favour the growth of 
Acacia trees which have big thorns that may play a role in introducing 
the organisms from the soil into the body (6,7). 
The prevalence of one type of organism or another at a certain area 
depends on several topographical factors like the temperature, rainfall, 
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type of soil and prevalence of vegetation as well as, the demographic 
features of the susceptible populations.  The climatology of 
maduramycosis in the Sudan was investigated by Balfour (1904), who 
determined that heat and aridity were favorable conditions for the 
causal fungi (4,7). 
In Africa most mycetoma cases are eumycetoma caused mainly by 
Madurella mycetomatis.  This is the commonest agent of mycetoma in 
Sudan, India and other tropical areas of Africa, but less so in Somalia, 
Yemen and Saudi Arabia. In Somalia, actinomycetoma is commoner 
than eumycetoma with S.somaliensis as the predominant actinomycete 
followed by Actinomadura madurae and then M. mycetomatis as the 
commonest agent of eumycetoma. 
In Saudi Arabia, the incidence is the same but infection with N. asteroid 
also occurs.   
In central Europe, the disease is rare but cases have been reported from 
Italy and Romania.  The eumycetoma were mainly caused by 
Monosporium apiospermum followed by M. mycetomatis and M. grisea 
and the actinomycetoma are caused by N. brasiliensis and rarely              
A. madurae(6). 
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In temperate regions, Pertriellidium boydi is the commonest cause of 
eumycetoma. In fact it is the commonest cause of eumycetoma in the 
United States and Canada. 
In a comprehensive study carried out by Mariat 1963, N. brasiliensis 
was found to be the commonest agent of actinomycetoma in central 
and South America and in recent study, it was found to account for 
85.6% of actinomycetes in Mexico.  This is followed by A. mudurae, S. 
somaliensis and A. pelletieri.   Actinomycetoma is commoner than 
eumycetoma in the Niger where the disease prevails.  In the Northern 
desert zone, the disease is predominatly caused by S. somaliensis, 
whereas in the Southern part, is caused by A. pelletieri, followed by N. 
brosliensis and A. madurae in descending order of frequency.  In 
Northern Nigeria, nocardia is the aetiological agent of 
actinomycetoma(4). 
In Sudan M. mycetomatis accounts for 71.4% of all mycetoma cases, S. 
somaliensis for 18%. A. madurae 5.3% A. pelletieri 2.7%  N. brasiliensis, C. 
lunata and A. nidulans for 2.6% (Abbott, 1956), (Lynch, 1964; Mahgoub, 
1965; Mograby, 1967), (Mahgoub, 1975).  
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Role of thorn in mycetoma: 
In 1931, Grantham-Hill studied 184 cases of mycetoma, he found that, 
in over 30% of this series of small yellow and black mycetomata of less 
than six month’s duration, thorns were actually found embedded in 
the growth after removal at operation.(8) Thorn may penetrate the 
human skin and thereby facilitate the entry of organisms into the body; 
such injuries may be produced by splinters of wood, sharp stones fish 
bones, nails etc.  Acacia thorn is capable of giving rise to granulomata 
and it is possible that such lesions provide a suitable nidus for the 
development of the fungus or actinomycetes (7). 
In Sudan, males are affected more than females in the ratio of 5:1.  This 
is a genuine sex difference and is not related to the greater outdoor 
activities of males because in certain areas in Sudan, males and females 
go out to work in the field side by side.  The disease is commoner 
between age groups 20-40 year; this being the earning group but no 
age group is immune.  Persons most commonly affected are 
cultivators, field laborers or herdsmen who are in contact with the land 
in endemic areas, but no occupation is exempted.  It is seen in doctors 
nurses, teachers, drivers and students.    
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Pathology of mycetoma: 
The histopathology of mycetoma has been brought to a reasonable 
standard of perfection by the work of MacKinnon and his associates 
(1954),  Destomes, Antre, Segretain, Mariat, Camain & Nazimoff (1958), 
Destombes & segretain (1962), Destombe (1964), Lynch (1964), 
Winslow & Steen (1964), Mahgoub & Elhassan (1972) and Mahgoub 
and Murray(1973)(7,10,14).  
Gross pathology: 
On cutting into a mycetoma lesion the knife passes readily through the 
mass exposing a section with an oily greasy surface in which the 
anatomical elements in many places are unrecognizable, being as if 
were fused together forming a pale, grayish mass.  Of all the structures 
tendons, nerves and fasciae seem to be the most resistant.  The most 
remarkable feature revealed by section is a network of sinuses and 
communicating cyst-like cavities of various dimensions from a mere 
speck to a cavity 2.5cm or more in diameter. 
Sinuses and cysts are occupied by material unlike anything else in 
human morbid anatomy.  In the black variety this material consists of a 
black brown, firm, friable substance which, in many places, fills the 
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sinuses and cysts; manifestly it is from this that the black particles in 
the discharge are derived.  In the white varieties the sinuses and cysts 
are also more or less filled with a white or yellowish roelike substance, 
evidently an aggregation of particles identical with those escaping in 
the corresponding discharge.  In the rare red variety the colour of the 
accretions is red or pink(9). 
Histopathology: 
For histopathological studies, tissue actually containing grains must be 
examined because the tissue reaction to wards fungi causing 
mycetoma is similar to that produced by other pathogenic fungi or 
even by bacteria, especially mycobacterium species. (7) 
Pathological features of mycetoma: 
Various stains can be used in the histopathological diagnosis of 
mycetoma: haematoxilin and easin (H&E), periodic acid schiff (PAS). 
Gomori methenamine silver and Craw.  For practical purposes HE is 
the most useful (7). 
Microscopic appearance of the commonest types of mycetoma in the 
Sudan. 
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Madurella mycetomatis: 
The grain is rounded oval or trilobed.   It has a compact cortex which is 
dark brown in colour and a lighter medulla.  The grain filaments are 
usually embedded in a hard brown cement matrix(10). Two main 
morphological types are identified. The filamentous which is the 
commonest and the vesicular one.  The filamentous consists of brown 
septated and branched hyphae that may be slightly more swollen to 
words the periphery.  The vesicular is composed large cells which look 
like vesicles.  Both types of grain can be found in the same lesion.  The 
inflammatory cellular reaction around the grain is variable.  There are 
three types of tissue reaction. 
In type (1): There is a zone of neutrophils in the vicinity of the grain 
and sometime within the grain causing its disintegration.  Outside this 
zone there is a histiocytes zone some of these cells have foamy 
cytoplasms and give a positive reaction of fat. Capillaries surround the 
neutrophils / histiocytes zone and they are occasionally surrounded by 
a layer of fibrin which contain lymphocytes, plasma cells, fibroblasts 
and some macrophages.  In type II, the neutrophils largely disappear 
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and are replaced by histiocytes and multinucleated cells.  At this stage 
the grain gets smaller and fragmented.   In type III   the grain material 
has largely or completely disappeared leaving a compact epithelioid 
grounloma without or with Langerhans giants cells.  The unique 
feature of M. mycetomatis is the formation of a capsule around the 
lesion.  In the bone there is no capsule but cavities filled with grains 
which may give the bone support, explaining the rarity of pathological 
fracture in mycetoma(1,10). Sclerosis and melonization of the host tissue, 
is in some manner, responsible for the formation of the cement 
substance (11). 
Streptomyces somaliensis: 
The grains are yellow in colour and hard in consistency, rounded to 
oval, dense and homogenous. Characteristically marks of the 
microtome knife are seen in the grain in the form of parallel cracks.  
The size of the grain is 30-200ug.  It contains a light purple or pink 
colour. Hyphal elements, embedded in cement can be visualized by 
Gram stain(10). Immunohistopathlogical examination of the mycetoma 
lesion showed that, the inflammatory reaction around the grain is of 
two types: In type I there are 3 zones: a neutrophil zone immediately 
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around the grain, an intermediate zone containing mainly 
macrophages, and a peripheral zone consisting of lymphocytes and 
plasma cells. In type II, there was no neutrophil zone, the grains being 
surrounded only by macrophages and giants cells(12) . Ultra-structurally 
the grain consist of heterogeneous and amorphous material arranged 
in an irregular and reticulate structure surrounding electron lucent 
areas between 1and 5 µm(13). 
Actionomadura madurae: 
On stain section it has a variegated pattern. The periphery of the grain 
is dense, homogenous and deep purple while the centre is less dense or 
even appears hollow.  Not infrequently the grain fragments into 
geometric fragments(4). 
Actinomadura pelletieri:  
In section the grain is rounded, oval or semi lunar.  It stains a purple 
colour and compact hyphae give it the appearance of “iron fillings” the 
periphery of the grain has a narrow deeply eosinophilic band(7). 
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Vascular changes in mycetoma: 
The arteries and veins in mycetoma lesion shows hypertrophy of the 
muscles with oedema. The lumen is narrowed but is not occluded 
completely(7) . 
Lymph node in mycetoma: 
Lymph node involvement was reported by El Hassan and Mahgoub 
(1972) in 13 patients. In three patients with mycetoma foot the inguinal 
lymph nodes were moderately enlarged, up to 4cm in their greatest 
diameter but no fungus was found in the sections. These nodes 
showed follicular and sinus cell hyperplasia. There was an intense 
plasma cell infiltration   in the medullary cords, and some of the cells 
contain Russell bodies. Melanin pigment and haemosiderin deposition 
were found in histiocytes in patients with fungal grains in the lymph 
modes. In early cases the architecture of the lymph node was 
preserved and the specific grains were scattered in the substance of the 
node. Neutrophils, polymorph, histiscytes and giant cells appeared in 
the vicinity of the grains. The rest of the lymph node showed reactive 
hyperplasia and deposits of haemosiderin and melanin. In more 
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advanced case, there were varying amounts of vascular fibrous tissue 
and in late cases no lymphoid tissue could be seen(14). 
Immunity in mycetoma: 
Humoral immunity:  
Both precipitating and complement fixing antibodies develop in 
mycetoma infection; they rise with activity and fall with recovery, 
disappearing with cure. Precipitin antibodies are used in diagnosis and 
monitoring treatment. They are measured by immuno-diffusion and 
counter-immuno- electrophoresis, both of which are sensitive and 
specific. Complement-fixing antibodies are less specific(15,16). All types 
of immunoglobulins were produced in abundance, though they were 
not protective(17).  
Cellular immunity: 
Mycetoma patients seem to be deficient in their cell-mediated 
immunity as measured by the tuberculin test, dinitrochlorobenzene 
reaction and lymphocyte transformation test when challenged with 
phytohaemagglutinin.  Type IV skin reaction are produced by purified 
protein antigens in actimmycetoma and in some cases of eumycetoma 
with Madurella antigens. Studies of mycetoma patients have 
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demonstrated some deficiency of cell-mediated immunity 
(CMI)(9,18,19,20). 
Clinical Presentation of Mycetoma: 
Mycetoma is five times commoner in males than females and generally 
occurs in adults between 20-40 years of age, although in endemic zones 
children and elderly may also be affected. No occupation is exempted 
but the disease typically affects cultivators, field labourers and 
herdsmen (21) . 
The term incubation period is difficult to apply to the disease because 
the time of infection is seldom known. However, the time of discovery 
of a mycetoma is variable and depends on various factors like the rate 
of growth, its site, the patients’ intelligence and extent of discomfort 
and pain if any. The duration of mycetoma can be any thing from three 
months to more than 20 years, but the majority of cases are detected by 
the second and third year. Though a patient is aware of early 
mycetoma, diagnosis is delayed due to the painless nature of the 
disease, fear of amputation and fatalism(7). The clinical triad of 
subcutaneous nodule, sinuses and discharge of grains is diagnostic. 
Mycetoma usually presents as a slowly progressive nodule at the site 
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of previous trauma. The most common site is the foot (70%) followed 
by the hand (12%), then the leg, thigh, buttock, perineum, head and 
neck, abdominal wall, orbit, mandible, air sinuses and intracranial and 
intra-spinal lesions (7,8,22,23,24,25,26,27,28). 
The subcutaneous nodule gradually increases in size and multiple 
secondary nodules may develop, suppurate and drain through 
multiple sinuses that may temporally close.  The discharge is usually 
serous, sero-sanguinous or purulent. Staphylococci or streptococci may 
occasionally be isolated. During the active phase of the disease, the 
sinuses discharge grains their colour depends on the type of organism; 
they may be black (M. mycetomatis), white (A. madurae), red (A.  
pelletieri), or yellow (S. somaliensis). The grains are of variable size and 
consistency. The clinical picture is almost uniform, irrespective of the 
causal species(1). 
The organism multiplies in the subcutaneous tissues, forming colonies 
that spread along fascial planes to involve skin, deep structures and 
bone. It eventually causes bone destruction with cavities deformity. 
Tendons and nerves are usually not affected. In eumycetoma the lesion 
grows slowly and remains encapsulated for a long time, whereas in 
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actinomycetoma it is more aggressive, more destructive and involves 
bone at an early stage.  
Genuine lymphatic spread of mycetoma to the regional lymph nodes 
have been confirmed by El Hassan and Mahgoub (1972) in 1-3% this 
type of spread is more common with actinomycetoma(14). Other causes 
of enlarged regional lymph nodes are secondary bacterial infection or 
local immunological reaction to the disease. Although mycetoma is 
generally painless, in about 18% of patients it is painful because of 
secondary bacterial infection or in some cases, due to bone expansion 
by the mycetoma(21). Lymphodema and varicose veins are rarely 
observed in mycetoma patients, the disease is rarely fatal but produces 
disabilities in its later stages. Constitutional disturbances in mycetoma, 
when occur, are usually due to secondary bacterial infection of open 
sinuses or concurrent infection(7).  
Primary osseous mycetoma without involvement of the subcutaneous 
tissues may occur in the superficial bone like the tibia and calcanium; 
here the disease is diagnosed radiologically or during surgical 
exploration(25). Massive bone involvement by mycetoma may rarely 
cause pathological fracture(26) . 
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The differential diagnosis of mycetoma includes soft tissue swelling 
such as thorn granuloma, fibrolipoma, neurofibroma, kaposis sarcoma 
and malignant melanoma. Osteogenic sarcoma and bone tuberculosis 
may have similar radiological appearances to mycetoma but 
sequestration does not occur in mycetoma. Primary osseous mycetoma 
must be differentiated from chronic osteomyelitis. Osteoclastoma and 
syphilitic osteitis.  It may be true to state that in endemic areas any 
swelling must be considered as mycetoma until the diagnosis is 
verified(25). 
The clinical presentation of mycetoma depends on many factors and 
that include, type of organism, disease duration host immune reaction 
and site of infection.  
Investigations in mycetoma: 
Patients from endemic areas are commonly familiar with the 
condition that they come with a ready-made diagnosis. But the 
question of early diagnosis, including identification of the 
pathogen, is now becoming more important on account of the 
following: 
• The increased recognition of the disease as a cause of disability. 
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• Its possible prevention or early treatment by minor surgery. 
• The revival of interest in its medical treatment. 
The clinical triad of a mass, sinuses and grains is diag\nostic but this 
needs to be supplemented by a number of investigations (2) . 
Radiology:  
Radiology is of special value in detecting bone involvement and in 
differentiating between actinomycetoma and eumycetoma. This in turn 
determines the nature of the surgical procedure that will follow. The 
most destructive and osteolytic mycetoma agent is A. pelletieri and N. 
brasiliensis. The effect is due to the granuloma and compression of the 
blood supply(28) . 
Three stage are recognized in the rediological appearances of 
mycetoma (Davies, 1958).  
• Soft tissue swelling. 
• Invasion of cortex from outside. 
•   Loss of definition in the cortical margin 
• Cavities formation.(7) 
In the early stages, there may be a soft tissue mass with obliteration of 
the fascial planes. Bone cortex may be compressed from outside by the 
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mass, producing scalloping which is followed by a variable amount of 
periosteal reaction. Sun-ray appearance and a codman’s triangle may 
be present, producing a picture similar to that of osteogenic sarcoma. 
There may be multiple cavities within normal-density bone. These 
cavities are large, few in number and have well defined margins in 
eumycetoma. In actinomycetoma they are small, numerous and their 
edges are ill-defined. The size of the cavities is a function of the 
grains(1) . Sequestration is commonly absent (2) . Radiology of the skull 
bones is purely sclerotic with dense bone formation and loss of the 
trabecular pattern(23) . 
Ultra sound imaging in mycetoma: 
The characteristic feature in ultrasonic examination of mycetoma has 
been described by Fahal and his colleagues. In eumycetoma lesion, the 
grains produce numerous, sharp hyper-reflective echoes and there is a 
single or multiple thick -walled cavities with no acoustic enhancement. 
In actinomycetoma the findings are similar but the hyper-reflective 
echoes are fine, closely aggregated and commonly settle at the bottom 
of the cavities. Ultrasongraphy is simple, non-invasive, quick, 
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reproducible and acceptable to patients. It delineates the extent of 
mycetoma better than clinical examination alone (29) . 
Fine Needle Aspiration Cytology of Mycetoma: 
Mycetoma has a distinct cytological features characterized by the 
presence of polymorphous inflammatory cells consisting of 
neutrophils, lymphocytes, plasma cells, histiocytes and  foreign body 
giant cell. To distinguish between actinomycetoma and eumycetoma, 
fine needle aspiration cytology was found to be as accurate as 
histopathology when grains are present (30). The technique is simple, 
quick and cheep.  
Culture in mycetoma: 
If grains are available, their morphology will indicate the nature of the 
disease but they should be cultured on Sabouroud’s agar to identify the 
organism and for in-vitro drug sensitivity tests, when medical 
treatment is used. Cultures of grains obtained from the sinuses may not 
be successful in some patients, because many grains may be dead and 
secondary bacterial infection may contaminate the culture. Better 
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results are obtained from direct culture of grains obtained 
surgically(7,21). 
Histopathology: 
The major advantage of histopathology is that the risk of mis-diagnosis 
by the isolation of contaminant fungus is eliminated and the biopsy 
can be taken even under relatively primitive conditions need not be 
kept sterile but may at once committed to a fixative. Biopsy is 
undesirable for fear of promoting lymphatic or local spread of the 
disease (7) . 
Serology of mycetoma: 
Serological methods of diagnosis are of great value in all fields of 
microbiology. The techniques are simple and reasonably specific. They 
are an aid to diagnosis in two ways; they detect the presence of 
mycetoma and differentiate between the organisms(15,16). This 
differentiation is essential from the point of view of treatment. 
Serological tests have certain advantages over conventional methods of 
culture and histopathology in that they avoid the need for biopsy which 
may help spread the fungus in the tissues; culture techniques are also 
cumbersome, time consuming and false results from chance 
  23
contaminants and examination by inexperienced workers are quite 
possible (7) . 
The history of immunology in mycetoma can reasonably be said to 
begun with the work of Ganzalez-Ochoa and Baranda (1953) who 
prepared antigens from Nocardia brasiliensis(7). In 1953 Murray and 
Moghraby tried two of the antigens made by Murray (1961), culture 
filtrate and carbohydrate antigen on patients with mycetoma in the 
Sudan. In that trial, culture filtrate was used. The test was carried out 
by injecting 0.1ml quantities of the culture filtrate antigen prepared 
from M. mycetomatis, S. somaliensis and S. pelletieri into the anterior 
surfaces of the forearms. In a series of six patients with 
actinomycetoma and 13 with maduromycetoma, those with the former 
reacted to actinomycete antigens, especially that from S. somaliensis, 
but those with maduromycetoma either failed to react to any of the 
antigens or reacted only to the antigen derived from M. mycetomatis (31)  
Immuno-diffusion and counter-immuno electrophoresis with 
appropriate antigens can define the causative organism with 
reasonable accuracy. There are cross reactions within the 
actinomycetoma group but not with fungus group. Using titer levels, 
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the progress of the disease can be checked since, falling titer will 
indicate response to treatment(16,32).  
Counter-immuno-electrophoresis is simple, efficient, economical, rapid 
and sensitive technique useful for routine diagnosis of early cases and 
especially for following up patients on treatment as well as for sera 
that are weakly positive by immunodoffusion. This is perhaps due to 
the fact that in immuno-diffusion molecules are lost by diffusing in all 
directions whereas in counter-immuno-electrophoresis they diffuse in 
one direction following the application of electric current(16). Although 
enzyme-linked immunosorbent assay (ELISA) has been attempted(33), 
counter immunoelectrophoreses still remain the serologic test of 
choice.  
Treatment of mycetoma: 
The morbidity of mycetoma in Sudan has not changed over the years 
and perhaps more patients are seen in hospitals and out-patient clinics 
every year. The outcome of surgical treatment alone has remained as 
leading to 80% recurrence rate. Prior to starting medical treatment it is 
absolutely necessary to determine the causal organism of mycetoma 
whether bacterium or fungus (34) .    
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Medical treatment of mycetoma: 
In vitro tests with antibiotic were carried out on mycetoma organism 
for the first time in Sudan in 1954(35).  Actinomycetoma chemotherapy 
is usually successful. Drugs that prove effective both in-vitro and in-
vivo are sulphonamides, notably Dapsone where  actinomycetoma is 
caused by Streptomyces somaliensis, A. madurae and Nocardia brasiliensis 
it is better to start with dapsone 100 mg twice a day and streptomycin 
sulphate 1 gm daily intra-muscularly for one months and then reduce 
the dose to one gram  on alternate days. If no response is seen after 
two months or if there is persistent anaemia and leucopenia, dapsone 
is replaced by co-trimoxazole two tablets, twice a day. In infections 
caused by A. pelletieri it is recommended to start with co-tri-mexazole 
and streptomycin sulphate combination since the organism is resistant 
to dapsone. In resistant cases, other drugs like rifampicin and 
sulphadoxine pyrimethamine (Fansidar) have been tried and proved 
effective in some patients. Recently amikacin alone or in combination 
with co-trimoxazole for those patients with no response to the first line 
treatment or who have a potentially hazardous site of infection. In 
eumycetoma, complete surgical resection of the lesion is advisable. 
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Surgical excision reduces the bulky lesion, will certainly reduce the 
length of treatment(28,34). In the case of eumycetoma due to                       
M. mycetomatis, the drug of choice is ketoconazole. In a dose of 200 mg 
twice daily, no significant side effects or biochemical abnormalities are 
seen. Liver function test are regularly carried out every month during 
treatment(36). Other regimes include, Itraconazole.  
In a trial of 15 patients with madurella mycetomatis ketoconazole was 
used in a dose of 400 mg, 300 mg and 200 mg daily. The result was as 
follows, five of 13 patients were completely cured and four improved. 
It is worth noting that the daily dose for those cured was 400 or 300 mg 
while those improved were on 200 mg/day. Treatment should 
continue for about 12 months or more if the bone was involved(36).  
Clinical trial on the treatment of mycetoma of the head and neck was 
reported by Gumaa, Mahgoub and Elsid. Fifteen cases were reported. 
Two due to M. mycetomatis and the remaining 13 due to 
actinomycetoma. All patients with actinomycetoma were given 
medical treatment as recommended by Mahgoub (1976). This was             
100 mg dapsone twice and streptomycin sulphate daily for one month 
and on alternate days thereafter for mycetoma caused by A. madurae 
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and S. somaliensis. Patients with A. pelletieri were given co-tri-moxazole 
and streptomycin sulphate. Criteria for response to treatment were 
mainly clinical and serological. They concluded that the majority of 
head and neck mycetoma was caused by actinomycetoma due to          
S. somaliensis (53%), followed by A. madurae (20%) and A. pelletieri  and 
M. mycetomatis (13.5% each). Those caused by S. somaliensis were 
considerably more difficult to treat than infection at other sites and 
hence some cases ended fatally. Others were maintained for long 
period of time at good clinical levels, but were never completely cured. 
Out of the eight patients with Streptomyces somaliensis in this series 
clinical and serological cure was obtained in only one case. The best 
response to chemotherapeutic treatment of head and neck mycetoma 
was obtained in cases of A. madurae given Dapsone and streptomycin, 
were the duration of treatment ranged from 15-48 months. Cases due 
to A. pelletieri showed good response to treatment with co-trimoxazole 
and streptomycin(23).  
A medical trial reported by Mahgoub (1976) on 144 patients with 
actinomycetoma showed that, 63% of them were cured, 21.5% showed 
great improvement in their condition and 11.1% showed some 
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improvement. The treatment was successful even when there was 
advanced bone involvement. The most effective treatment included 
dapsone and streptomycin sulphate or co-trimoxazole and 
streptomycin sulphate. Sulphadoxine-pyrimethamin (Fansidar) and 
streptomycin or rifampicim and penicillin showed also good results. 
What ever regime is used supportive treatment with ferrous sulphate 
and folic acid should be given. Follows up with regular hemoglobin 
and total white count estimation must be provided(38). Clinical 
improvement is judged by reduction in the tumour size and closure of 
sinuses, radiology and ultrasonography. Ketoconazole and 
itraconazole have been tried with some success. However, these drugs 
are expensive and therefore not readily available in endemic areas. 
Another disadvantage is that such drugs must be given for long period 
(from 6 months to 10 years) to effect cure(1) . 
Dose of the drugs: 
Injections of streptomycin sulphate are give intramuscularly (IM) at        
14 mg/kg/day for the first month and on alternate days thereafter. 
The usual daily dose of co-trimexazole is 14 mg/kg twice daily. The 
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dose is lowered to 7 mg/kg twice a day if there is reduction in either 
hemoglobin or the white blood cell count.  
Dapson tablets are given usually at 1.5 mg/kg morning and evening; 
in a few cases where anaemia and leucopenia appears, 0.7 mg/kg is 
given twice daily. Ketoconazole is given in a dose of 400 – 600 mg/day 
in form of rablets. 
 Surgical treatment of mycetoma: 
Surgical treatment of mycetoma ranges from biopsy, local excision to 
mass reduction and occasionally to amputation of an affected limb.  
The aim of surgical treatment is complete removal of the lesions. 
Actinomycetoma has an ill defined border and therefore a margin of 
health tissue should always be excised with the tumour. In 
eumycetoma the tumour is encapsulated and great care must be taken 
not to rupture this capsule(7). Great care must be exercised during 
surgery to minimize the spread of grains along the fascial phanes if 
recurrence is to be avoided. 
Surgical mass reduction of a lesion that can not be completely excised 
greatly facilities the response to medical treatment.  Approximately 
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one-quarter of all mycetoma patients require amputation of the 
affected limb(39).  
To avoid the socially unpleasant consequence of amputation, a 
programme of extensive repeated excision of diseased tissue, including 
bone, may be carried out preferentially. Such debulking procedures are 
carried out in about one-fifth of patients. The recurrence rate after 
surgical treatment is high, ranging from 20 to 90 percent.  Medical 
treatment before and after surgery should be used to reduce the 
incidence of recurrence.  
S. sahariah and his associates (1978) studied ten cases of mycetoma of 
the lower extremity. Six were treated by conservative methods 
(chemotherapy and immobilization) of the affected part, while the 
remaining four were submitted to surgery. Four out of the six from the 
first group had recurrence and had been submitted to surgery. 
Recurrence occurred in only one case from the second group and 
required an above knee amputation while the remaining three were 
free of disease and were well rehabilitated. They claimed that 
indication for surgery has been that either the disease process was 
limited to soft tissue alone and no bony involvement or the resistant 
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cases with bony involvement not responding to repeated long-term 
conservative therapy(40). If after excision, any doubt remains regarding 
contamination of the field with grains from the excised tumour it is 
wise to flood the wound with tincture of iodine, mop it out well and 
leave the wound opened to granulate from the base(7). 
In 1964, in the province hospital at El-obied in the west of Sudan 
mycetoma was responsible for 50% of below knee amputation(7).  
Lynch (1964) suggested surgical intervention as the treatment of choice 
whether it is radical or conservative. He presented six hundred and 
twenty (620) cases of mycetoma. Out of these and sixty four patient 
ended in amputation. He reported a recurrence rate of 25% within one 
to 3 years and attributed this recurrence to the difficulty in operation to 
identify the limits of spread of the mycetoma(39). 
The rate of postoperative recurrence in mycetoma is high and may 
reach 80% (Moghraby, 1964). In the main it is due to inadequate 
removal of the organism. More dangerous in this respect are attempts 
by inexperienced young medical staff to remove localized mycetoma 
under local anaesthesia in outpatient department. Mycetoma should be 
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regarded seriously, because the extent of the tumour is often much 
more than appearances suggest (7).         
Mycetoma in the Sudan: 
Sudan seems to be the homeland of mycetoma. Lynch in 1964 
estimated the incidence of mycetoma in the Sudan as 300-400 new 
hospital cases annually, this figure does not take into account the 
considerable number of out patient  and those seen at peripheral 
dispensaries where qualified doctors might not even be present. 
However recent estimates of mycetoma have not been reported. 
Mycetoma seems to have been known in Sudan before the advent of 
modern medicine, by its present common name of “Nebit” meaning 
growth. Treatment by cautary and/or amputation was practiced by 
“Fikkis” during the time of Mahdeya (1885-1899)(8). 
However the first documented report of a case of mycetoma in the 
Sudan was published by Balfour in 1904. He noted that the disease was 
common amongst Northern Sudanese, the foot was affected most and 
that the commonest type was the black grain variety(7). These findings 
were documented hundred years ago and are still valid.   
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Chalmers and Archibald (1916-1918) gave the definition of mycetoma 
and its classification into maduromycosis and actinomycetoma and 
this was followed by Grantham-Hill in 1931. Thereafter, many authors 
reported on mycetoma, Abott (1956), Murray (1960), Lynch (1964), 
Mogharaby (1967), Mahgoub (1964), El-Hassan (1972), Gumaa (1974), 
Fahal (1992). 
In 1968 with the help of the ministry of Overseas development, United 
Kingdom, the World Health organization (WHO), Ministry of Health, 
Sudan and the University of Khartoum, set a project to study 
mycetoma in the Sudan and to conduct therapeutic trials was 
established by Mahgoub, at Khartoum North civil Hospital. Reports 
from this project emphasized the seriousness of mycetoma as a major 
mycological health problem in the Sudan. It seems that mycetoma is 
more prevalent in the central part of the country.  The clinical picture 
of mycetoma is almost uniform irrespective of the causal organism.  
Most of the cases seen in the Sudan are massive lesions.  In endemic 
areas (e.g. Gazira) the local people are more familiar with the condition 
and but still they do not present early for medical advise. The most 
common aetiological agents of mycetoma in the Sudan are Madurella 
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mycetomatis which account for about 70% of all recorded cases,                  
S. somalienses, Actinomadura madurae and A. pelletieri for 10% the 
incidence of mycetoma in different anatomical sites. The foot is 
commonly affected in 70% the hand in 12%, followed by the leg, thigh, 
knee and other rare sites(21). 
Since the establishment of the mycetoma clinic, a lot of work has been 
done by Mohagoub, Hassan and Gumaa(7,14,19,28,40). .Concerning the 
diagnosis, new aetiological agents and drug treatment.  Through this 
they illustrate many important points which attract our attention to 
this endemic problem which can be summarized as follows: 
i. Mycetoma is a major surgical problem. 
ii. Recurrence rate after surgical excision is very high. 
iii. Reported to occur in rare sites like intracranial 
iv. It is important to differentiate between actinomycetoma, which can 
be cured by chemotherapeutic agents and eumycetoma which is 
resistant to drug therapy. 
v. Combination of drugs gave better results in the treatment of 
actinomycetoma. 
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OBJECTIVES 
 
During the last few decades there are new trends in the management 
of Mycetoma patients. Many antifungal drugs especially against 
eumycetoma have been used. Medico-surgical approach for the 
management of mycetoma is adapted in many centres in order to 
shorten the length of treatment and hence to reduce the treatment cost 
and to avoid recurrence. There is no excuse now for mutilating surgery 
or amputation of limbs in the management of mycetoma. Recurrence is 
a night mare in mycetoma and its causes were not studied before. 
 This study was set out at the Mycetoma Research Centre with the 
following objectives: 
 To determine the recurrence rate among the mycetoma patients . 
(I)  To determine the outcome of the combined medicosurgical 
approach for the management of mycetoma patients.  
(II) To identify predictors of recurrence in mycetoma.  
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PATIENTS AND METHODS 
This study was conducted at the Mycetoma Research Centre, at Soba 
University Hospital, Khartoum, Sudan, which is the only referral 
centre in the Sudan.  Patients seen in the centre are from all over the 
country. There was no selection of patients. It is a retrospective 
hospital based study.  
The study included 3222 patients with confirmed mycetoma seen in 
the centre in the period from January 1994 to December 2003. The 
diagnosis of mycetoma was confirmed clinical, radiological, cytological 
and histo-pathological techniques. There were 2421 males and 801 
females. The age ranged from   4 to   85 years with a mean of 27.4 years.  
The records of these patients were carefully reviewed and the 
information was recorded in data filling sheet (appendix 1).  This 
information included personal, medical history, history of previous 
surgery and the type of anesthesia used as well as chemotherapeutic 
agents used for each patient. The clinical findings which included loco-
regional examination was included. The operative findings were 
recorded. The radiological examination finding of the affected parts 
and other investigations were recorded.  
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All patients were investigated before treatment and that included liver 
function tests, blood urea, full blood count, Ultrasonic examination of 
the lesions.  
The patients were started on chemotherapy in the form of: 
1- For eumycetoma ketoconazole orally 400-800 mg daily in two 
divided doses. 
2- For actinomycetoma streptomycin sulphate (14mg/kg) daily for one 
month and thereafter on alternate days, combined with dapsone 
100mg b.d or co-trimoxazole 14 mg/kg twice daily.  
Usually the patients had these treatments before and post operatively 
until they are cured. The operative findings were documented.  
The criteria for cure were, healing of sinuses, the size of the affected 
region returned to normal, radiological abnormalities disappearance 
and three consecutive negative counter-immuno-electrophoresis 
results (C.I. E). 
The data was tabulated and analyzed using SPSS computer program. 
The methods of predicting recurrence was appearance of swelling with 
or without sinuses and a positive C.I.E test.   
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RESULTS 
This retrospective study was conducted at the Mycetoma Research 
Centre, Soba University Hospital, Khartoum, Sudan. The records of 
patients attending the mycetoma clinic from January 1994 to December 
2003 were carefully reviewed and that included 3222 with confirmed 
mycetoma.  
There were 2421 males (75.1%) and 801 females (24.9%) with sex ratio 
of 3:1 (Fig. 1). Their ages ranged between four years and 85 years with 
a mean age of 27.3 years. Most of the patients (71.3%) were in the age 
group 11- 30 years.  Few patients (2.6%) were less than 11years and 
2.9% of them were more than 60 years old (Fig. 2). 
The majority of the patients (56.3%) were from the Central Sudan. That 
was followed by patients from Khartoum State (17.2%) most of them  
were immigrant from other parts of the Sudan and Western Sudan 
(16%). Few patients were from the North (5.1%) and the East of the 
Sudan (4.9).  Only eighteen patients (0.6%) were from the South            
(Table 1). 
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Most patients had eumycetoma (80.1%) and actinomycetoma was 
diagnosed in 19.9% of the patients (Fig.  3). 
The majority of the patients were students (30.2%), farmers (17.3%), 
workers (15.2%), and 9.2% of them had lost their jobs due to illness 
(Table 2). 
The duration of illness varied between eight months to 57 years. In 
this study, 823 patients (25.6%) had mycetoma for less than one year. 
There were 437 patients (13.6%) with illness duration of more than 10 
years (Fig.  4). 
Only 22.3% of the patients had history of trauma at the mycetoma site, 
56.9% failed to recall history of trauma while 20.8% are not sure 
whether they had trauma (Fig. 5).The study revealed that 45.1% of the 
patients had recurrent mycetoma while 54.9% presented for the first 
time (Fig. 6).  
The foot was the commonest (79.1%) affected site. Both feet were 
almost equally affected. The hand was the second commonest (7.3%) 
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site followed by the leg and knee region. Other sites were affected as 
well (Table 3). 
Clinically mycetoma lesion is classified into small lesion (less than 5 
cm), medium lesion (6 – 10cm) and large lesion (more than 10 cm) 
according to the diameter of the mass.    In this review 41.8% patients 
had small lesions, 28.8% had medium lesion and 29.4% had large 
lesion (Fig. 7). 
Active sinuses were documented 1801 patients (57.4%), healed sinuses 
in 668 patients (21.3%) while 666 patients (21.2%) had no sinuses at 
presentation (Fig.  8). Enlarged regional lymph glands were found in 
16.4% of the patients while most of the patients (83.6%) had no 
palpable regional lymphadenopathy (Fig.  9). 
Three thousands one hundred and six patients had radiological 
examination of the affected sites. The examination was normal in  
51.4% of them, it showed soft tissue swellings in  27.7% of the patients   
20.8% of them had evidence of bone involvement  (Fig. 10).  
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Most of the patients (92.9%) had surgical excision and the recurrence 
rate was 24% (figs 11, 12). The recurrence was documented in 542 
males (26%) and 122 females (17.9%) (Table 4). That was statistically 
significant    (P value < 0.05). 
Out of the 80 patients who were less than 11 years old, 10 patients 
(12.5%) had recurrence after surgical excision. While patients more 
than 60 years old had 41% recurrence rate. That is statistically 
significant (P value < 0.05) as shown in (Table  5). 
The recurrence rate in eumycetoma patients was 19.9% while in 
actinomycetoma it was 42.8% (Table 6). That is statistically 
significant (P. value < 0.05).  
In patients with illness duration less than one year the recurrence rate 
was 10.7%, and in patients with disease duration of more than 10 years 
the recurrence rate was 40 .5% (Table 7). That is statistically significant 
(P. value < 0.05).   
The recurrence rate was equal in left and right foot with incidence of 
23.5% and 23.8% respectively. The recurrence rate in the hand 
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mycetoma was 14%. Head and neck mycetoma had recurrence of 
30.8% while leg and Knee mycetoma was 34.9% (Table 8). That is 
statistically significant (P. value < 0.05).  
The bigger the size of the lesion the higher the recurrent rate.  All 
patients  with lesion more than 10 cm had recurrence while those with 
lesion less than 10 cm had no recurrence (Table 9). That is statistically 
significant (P. value < 0.05).  
In lesions with no sinuses the recurrence rate was 9.6%, in lesions with 
active sinuses the recurrence rate was 25.8% while in lesions with healed 
sinuses the recurrence was 34.2% (Table 10). That is statistically 
significant (P value < 0.05).  
In patients with no palpable regional lymphadenopathy the recurrence 
rate was 15.9%, while those with lymphadenopathy the recurrence rate 
was 53.2% (Table 11). That is statistically significant (P value < 0.05).  
The incidence of recurrence in patients with radiological soft tissue 
masses was 22.5%, and in patients with bone involvement was 49.9%. 
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The recurrence rate in patients with normal radiological examination 
was 15.8% (Table 12). That is statistically significant (P. value < 0.05).   
The recurrence rate in patients with previous surgical intervention was 
24.6% while patients with no previous surgical intervention had 
recurrence rate of 23.6% (Table 13). That is statistically significant         
(P. value < 0.05).  
Out of 1268 patient who had previous surgical treatment, only 218 
patients (17.2%) had post operative medical treatment (Table 14). 
In 1454 patients with previous surgical intervention, 52.2% of them 
had that done under local anaesthesia, 38.9% under general 
anaesthesia, 7% under spinal anaesthesia while 1.9% do no recall the 
type of anaesthesia used (Table 15). 
Out of 664 patients with recurrence 99 patients (15%) had their 
recurrence within the first year. 47% had their recurrence during the 
second year while 11% recurred during the 4th year (Table 16). 
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One thousands and thirty patients (49.1%) continue their treatment for 
one year, 22.9% for 2 years and 16.8% for 3 years while 11.2% continue 
their treatment for up to four years (Table 17). 
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Figure 1: Sex distribution in mycetoma patients  
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Figure  2: Age distribution of mycetoma patients  
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Figure 3:  Type distribution of the mycetoma  
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Figure 4: Illness duration among the mycetoma patients  
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Figure 5: Incidence of trauma among the mycetoma patients  
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Figure 6: Incidence of previous recurrence among mycetoma patients  
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Figure 7: Size distribution of the mycetoma patients  
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Figure 8: Sinuses distribution among the mycetoma patients  
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Figure 9: Incidence of lymphadenopathy among the  
mycetoma patients   
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Figure 10:  Radiological findings in the mycetoma patients  
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Figure 11: Incidence of surgical intervention done at the MRC  
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Figure 12: The recurrence rate among patients treated at MRC   
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Table 1: Geographical distribution of the mycetoma patients  
554 17.2 
1814 56.3
516 16.0
18 .6
157 4.9
163 5.1
3222 100.0 
Khartoum 
Middle 
West 
South 
East
North 
Total 
Frequency PercentAddress 
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Table 2: Occupations of the mycetoma patients  
 
407 12.9
482 15.2
546 17.3
30 .9
290 9.2
452 14.3
956 30.2
3163 100.0
 
Occupation 
house wife 
worker 
farmer 
clark 
jobless 
others
student 
Total
Frequency percentage 
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Table 3: Mycetoma site distribution among the patients 
1227 39.1 
1256 40.0 
216 6.9 
58 1.8 
46 1.5 
39 1.2 
230 7.3 
8 .3 
18 .6 
19 .6 
3 .1 
9 .3 
8 .3 
3137 100.0 
Site Group 
Left Foot 
Right Foot 
Leg & Knee 
Thigh 
Buttock 
Arm & forearm
Hand 
Chest wall 
Head & neck 
Back 
Abdominal wall
Perineum 
Others 
Total 
Frequency 
 
Percentage  
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Table 4: Recurrence rate and gender 
Gender  Frequency Percentage 
Female  122 17.9% 
Male  542 26.0% 
 
          P. value 0.00 
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Table 5:  Recurrence and age 
Age group (in years) No. of patients Percentage 
1 - 10 10  12.5 
11 - 20 158 18.3 
21 - 30 250  21.9 
31 - 40 98 28.2 
41 – 50 73 46.5 
51 - 60 42 43.8 
> 60 32 41.0 
                P. value 0.00 
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Table 6: Recurrence rate and mycetoma type 
Type  No. of patients Percentage 
Eumycetoma  401 19.9 
Actinomycetoma  200 42.8  
                P. value 0.00 
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Table 7: Recurrence rate and illness duration 
Duration (in years) No. of patients Percentage 
< 1 80 10.7 
1_2 104 22.7 
2_4 126 23.8 
4_6 94 28.8 
6_10 125 35.3 
>10 134 40.5 
            P. value 0.00 
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Table 8: Recurrence rate and mycetoma site 
Site group No. of patients Percentage 
Left foot 252 23.5 
Right foot 259 23.8 
Leg & knee 61 34.9 
Thigh 18 39.1 
Buttock 9 23.1 
Arm & forearm 7 21.2 
Hand 30 14.0 
Chest wall 1 16.7 
Head & neck 4 30.8 
Back 5 41.7 
Perineum 3 33.3 
Others 2 40 
                 P. value 0.00 
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Table 9: Recurrence rate and mycetoma lesion size   
Size (cm) No. of patients Percentage 
< 5 0 0 
6 – 10  0 0 
> 10  664 100 
                P. value 0.00 
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Table 10: Recurrence and the presence of sinuses 
Sinuses No. of patients Percentage 
None  59 9.6 
Present  395 25.8 
Healed  209 34.2 
           P. value 0.00 
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Table 11: Recurrence rate and regional lymphadenopathy 
Lymphadenopathy  No. of patients Percentage 
None  394 15.9 
Present  218  53.2 
           
             P. value 0.00 
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Table 12: Recurrence rate and radiological findings of the 
 affected part 
Radiology  No. of patients Percentage 
Soft tissue swelling 177 22.5 
Bone involvement 270 49.9 
Normal 213 15.8 
        P. value 0.00 
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Table 13: Recurrence rate and previous surgical excision of 
mycetoma done elsewhere 
Previous surgery  No. of patients Percentage 
No  363 23.6 
Yes  301  24.6 
        P. value 0.53 
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Table 14: Recurrence rate and previous medical treatment 
Previous treatment  No. of patients Percentage 
Yes  218 17.2  
No  1050 82.8 
            P. value 0.00 
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Table 15: Type of anaesthesia used in patients with 
 previous recurrence   
Anaesthesia  No. of patients Percentage 
Local  759 52.2  
Spinal  103 7.1 
General  565 38.9 
Other  27 1.9 
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Table 16: Time of recurrence after complete cessation of treatment  
Time in years No. of patients Percentage 
1 99 15% 
2 312 47% 
3 180 27% 
4 73 11% 
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Table 17: Treatment duration for the cured mycetoma patients 
Duration (in years) No. of patients  Percentage 
1 1030 49.1 
2 482 22.9 
3 353 16.8 
4 233 11.2 
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DISCUSSION 
This study reviewed the records of 3222 patients with confirmed 
mycetoma seen at the Mycetoma Research Centre, Khartoum, Sudan. 
This centre is the only referral centre in the Sudan hence the study may 
be meaningful. The sex ratio is 3:1 this is in line with other recent 
observations but it is not in agreement of past reports from Sudan, 
where most of the reports showed male predominance 5:1(1,2,7,41). 
Although this may be genuine sex difference the male predominance 
in mycetoma is not clear as in endemic areas females are committed to 
out door activities as males. It is interesting to note that during 
pregnancy the disease is more active and aggressive it may be due to 
changes in hormonal environment or the immune status of the host 
during pregnancy.  
No age group was exempted in this study, though infection was rare at 
extremes of life. Peak incidence of mycetoma was in the age group 11-
30 years this is a younger age group when compared with pervious 
reports where the peak incidence was in the age group 20-40 years(2). 
This may indicates patients are getting the infection at a younger age 
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group, this is serious as these are the most active members of the 
society. However, this may reflect increase awareness of the 
community with the disease and their earlier presentation.   
The majority of patients were from the Gezira area, this in line with 
previous studies; Murray (1960), Moghraby (1967) and Mohgoub 
(1969).  Most of the patients had eumycetoma.  The second commonest 
region (16%) was the Western Sudan and most of them had 
actinomycetoma. Few patients were from the South. These facts clearly 
demonstrate the geographic distribution of mycetoma. Health 
education should be conducted in these endemic areas to encourage 
patients to present early to avoid the consequences of late disease 
which can not be less than amputation.  Still there is controversy about 
the route of entry in mycetoma but probably in these areas the 
causative organisms are found in abundance and an intermediate host 
may be present which enhance the spread of the disease. Organisms 
were isolated from soil by Agello and Mahgoub (1979)(42). 
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Eumycetoma remain the commonest type (81.1%) and this in line with 
reports by Moghraby (1971), Abbott (1956), Awooda (1990), and that 
could be explained on geographical and ecological basis. 
Mycetoma is seen more conventionally in farmers, field workers and in 
herdsmen and in endemic areas people of other occupations are also 
affected(39). Awooda (1990) found no significant difference between 
outdoor and indoor activities(41). In this study, students were affected 
most. The explanation of this is not clear. It may be due to increased 
activity in the field and their direct contact with the soil, increase in the 
educational facilities in these endemic areas and involvement of these 
students in field activities. 
Due to the prolonged illness eventually most of these students are 
unable to continue their education that has many social and 
economical consequences. 
The duration of mycetoma prior to presentation varies from three 
months to 20 years but the majority of patients present within the 
second and third year of the illness and that can be explained by the 
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lack of health education, the painless nature of the disease, fear of 
amputation which still in some centre is the only available treatment 
for advanced disease. (7).  In this study 25.6% of the patients presented 
within the first year this may indicates increase in the awareness of the 
disease especially in endemic areas. 
Most of the patients failed to recall history of trauma at the site of 
mycetoma. This contrasts the general assumption that mycetoma is 
caused by traumatic inoculation of the organism into the subcutaneous 
tissue. Grantham- Hill (1931)(8) showed that in 30% of his patients who 
had less than 6 month duration of illness thorns were actually found 
embedded in the growth during surgery that may be due to the fact 
that during those dates thorn pieces were quite common compared to 
the present time. This low incidence of local trauma may be explained 
by the triviality of trauma which may be passed unnoticed. However, 
further studies to ascertain the route of entry is needed.     
Mycetoma tends to affect sites of the body that come in contact with 
the soil. Interesting to note that isolation of the organisms from the soil 
is difficult but can be(42). Inspite of these observations mycetoma is 
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commonly documented in the foot and right hand and this in line with 
other reports(7,39,41,43). The explanation of this is unclear further studies 
are needed to explain this.    
The clinical presentations in our series are in accordance with other 
reports. However, the incidence of regional lymphadenopathy is 
higher than the reported previously (3%)(14). The lymphadenopathy is 
commonly due to secondary bacterial infection, genuine lymphatic 
spread of the organism or due to local immune response.  
Most of the patients had normal radiological findings and that can be 
explained by the predominance of eumycetoma in which the disease is 
commonly localized and it invades the bone at a later stage, while 
these patients presented relatively early.   
In our series, 45.1% of the patients had previous surgical excision 
elsewhere. Most of the excisions were done by untrained junior 
medical personnels and done under local anaesthesia in small health 
facilities.   
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In the centre surgical excisions have been undertaken in 2762 patient 
and the majority (76%) had been cured. The incidence of recurrence in 
this series was 24% and the evidence was appearance of a mass and a 
positive serology (CIE). This low recurrence rate is certainly due to the 
combination of medical and standard surgical procedures offered to 
these patients. 
Lynch (1964) had recurrence of 25% when he studied 620 patients with 
approximately quarter undergone amputation(39).. Saharia (1978) 
reported 25% recurrence rate(45). Awooda (1990) reported 90.8% 
recurrence rate and attributed this high recurrence rate to the fact that 
the lesion is considered minor, done by untrained doctors and health 
personnel, in the minor theatre, under local anaesthesia without any 
precousions(41). 
The recurrence rate in males and females were 26% and 17.9% 
respectively. The predominance of recurrence in males may be related 
to the difference in incidence between males and female.   
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The recurrence rate increased gradually with the increase in the 
affected age group to reach its maximum at the fifth decade 46% and 
decreases gradually to reach 41% above the age of 60 years. This may 
be due to progressive unreported lesion. 
The recurrence rate in eumycetoma was 19.9% while in 
actinomycetoma was 42.8%. This is in agreement with report by Lynch 
(1964) who reported higher recurrence rate in actinomycetoma (32%) 
than the eumycetoma (25%). This could be due to the more aggressive 
nature of actinomycetoma, rapid spread of the disease along the fascial 
planes due to lack of capsule around the lesion and early bone 
invasion compared to eumycetoma.  
The recurrence rate was found to be related to the size of the lesion, the 
bigger the size the higher the incidence. This explained by the difficult 
excision and poor response to medical treatment. Hence early 
detection and treatment are important to reduce the recurrence rate 
and health education and availability of medical care are important to 
achieve this.  
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There is no significant difference in recurrence rate between the left 
and right foot which is 23.5% and 23.8% respectively. The least site of 
recurrence is the hand 14% and the highest was found to be the back 
(40.7%) followed by thigh (39.1%), the low recurrence in the hand may 
be due to the consciousness of the patient about the function of the 
hand, while they can drag the affected foot for sometime. The high 
recurrence rate in the back could be due to the technical problems of 
applying the tourniquet and difficulty in identifying the lesion 
margins and its complete removal in the absence of a bloodless field.  
The recurrence rate was more commonly seen with lesions which had 
sinuses compared with solid lesion. Sinuses are commonly seen in long 
standing lesions. Abbott (1956) reported that, in late stages of 
mycetoma growing points meet and fuse round muscles and tendons 
and sinuses leading from the collection formed(43).  
The presence of enlarged regional gland is associated with a recurrence 
rate of 53.2%. Patients with no palpable regional lymph glands had 
recurrence rate of 15.9%. Regional lymph node enlargement draining 
the site of mycetoma is not uncommon. This can be due to secondary 
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bacterial infection genuine lymphatic spread of the fungus or due to 
local immune response. Enlarged regional lymph gland is possibly 
time related and related to the primary size(41). That may explain the 
association between recurrence and the regional lymphadenopathy. 
The recurrence rate is high in patients with bone involvement 49.9% 
compared to 22.5% when only the soft tissue is involved and 15.8% in 
the normally appearing radiology. The importance of radiology in 
follow up and assessment of cure had been stressed by Kamalam et al 
(1975)(44). Bone involvement indicates an advanced state and bigger 
lesions and therefore challenging medical and surgical treatment.  
In patients with previous surgery out side the Mycetoma 
Research Centre 17.2% received medical treatment and 82.8% do not 
received chemotherapy. The importance of combined medical 
treatment and surgery have been stressed by some(34), where 
chemotherapy facilitate surgery shorten the duration of the medical 
treatment.  
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Within the group of patients with previous operation out side                 
Mycetoma Research Centre 52.2.% were done under local anaesthesia, 
39.9% under general anaesthesia and 7% under spinal anaesthesia. 
Local anaesthesia should not be used. It is reported that local 
anaesthesia can help spread of mycetoma even to the sites of injection 
of local anaesthetic(39). The clinical appearance of the lesions is not 
indicative of the actual size of the lesions and in most cases local 
anaesthesia is not adequate and considerable portion of the lesion is 
left behind and hence the higher recurrence rate under local 
anaesthesia.    
The majority of patients 47% developed recurrence during the second 
year following cessation of treatment, and 27% had recurrence after 3 
years. This fact emphasis the importance of close follow up of patients 
after treatment for early recurrence detection and treatment. Ultrasonic 
and cytological examination of the suspected lesions can give early 
diagnosis.  
Treatment of mycetoma might need to be continued from few months 
to many years which can be for up to 10 years(38). Most of the patients 
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(49.1%) had medical treatment for long period and a mean of one year 
duration. These patients are of a low socioeconomic status and they 
need financial support to avoid interrupting their treatment and the 
development of drug resistance. New, safe and cheap antifungal drugs 
are needed to shorten the treatment duration and to avoid the drugs 
side effects.   
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CONCLUSION 
From the study the following can be concluded: 
• The recurrence rate was 24%. 
• Recurrence is commonly seen in males than females with a ratio of 
3:2. 
• The recurrence rate in actinomycetoma (42.8%) was higher than in 
eumycetoma (19.9%). 
• The recurrence rate was higher in patients with large lesions. 
• The incidence of recurrence in patients with soft tissue on 
radiological was 22.5%, and in patients with bone involvement it was 
49.9%. The recurrence rate in patients with normal radiological 
examination was 15.8%.   
• The incidence of recurrence increased with the duration of the 
disease. 
• The hand mycetoma had the least recurrence rate (14%) while back 
mycetoma had the highest recurrence (41.7%). 
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• Patients with enlarged regional lymph glands had recurrence rate of 
53.2% and those with no palpable regional lymph glands had 15.9% 
incidence. 
• The recurrence rate in the absence of sinuses was 9.6%,while in the 
presence of sinuses it was 60%.   
• Late and advanced mycetoma still remains a dilemma that tends to 
prohibit the conservative approach. 
• Most of the recurrence was observed during the second year (47%) 
and the third year (27%). 
• 49.1% achieved cure during the first year, while 11.2% continued 
treatment for up to 4 years. 
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RECOMMENDATIONS 
• It is essential to differentiate between eumycetoma and 
actinomycetoma before starting any treatment.  
• Medico-surgical approach is highly recommended in all cases to 
reduce the recurrence rate. 
• Mycetoma should be regarded seriously and managed carefully.   
• Early diagnosis and complete surgical removal combined with 
adequate medical treatment is highly recommended. 
• New drugs are needed to effect cure, to reduce the recurrence rate, 
to reduce the drug side effects and to shortening the treatment 
duration. 
• Mycetoma Centers should be established in endemic areas and all 
those concerned should work as a team for better outcome. 
• There is no need for mutilating surgery or amputation.  
• Health education for those at risk and the use of protective foot 
wear. 
• There is need for more advocacies to increase awareness of general 
duty doctors about correct medical management.  
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University of Khartoum 
Postgraduate Medical Studies 
Mycetoma Data Sheet 
No:…………………………………………………………. 
Hospital No.:…………………………………………. 
Date :……………………………………………………… 
Name :………………………………….… Age:…………..  sex:……………. 
Occupation:…………………………………  Locality:……………………….. 
Address: 
           1:………………………………………………………………………………. 
           2:………………………………………………………………………………. 
           3:………………………………………………………………………………. 
CLINICAL HISTORY: 
           Onset :…………………………………………………………………….. 
           Duration :………………………………………………………………… 
           Course :……………………………………………………………………. 
           Discharge :………………………………………………………………. 
           Pain :………………………………………………………………………… 
           Trauma :…………………………………………………………………… 
           Others: …………………………………………………………………….  
Medical Problems :……………………………………………… ……………………..  
Previous Surgery :………………………………………………. No:…………............... 
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Anaesthesia :…………………………..………………………. Date :……… …… 
Previous treatment:………………………………..Drug :…………………………………… 
Family History :……………………………… ………………………………… 
CLINICAL EXAMINATION : 
Site:…………………………………………… ……………………………………………….. 
Size:……………………………………………………………………………………………… 
Consistency:…………………………………………………………………………………… 
Sinuses:…………………………………………. Healed ………………………………… 
Grains:…………………………………………………………………………………………… 
Discharge:……………………………………………………………………………………… 
Glands:………………………………………………………………………………………… 
Varicose Veins:…………………………………………… ……………………………. 
Temperature:………………………………………………………………………………. 
Sweating:……………………………………………………………………………………… 
Stage :……………………… ……………………………………………………. 
LABORATORY INVESTIGATIONS: 
CULTURE OF PUS: 
1.Organisim:………………………..……Drug sensitivity ……………………………….. 
2. Organism:……………………………..Drug sensitivity………………………………… 
3. Organism:……………………………..Drug sensitivity……………………………….. 
Culture of grain :……………………………………… ……………………………….. 
Serology :……………………………………………………… …………………… 
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Hemogram:  
   HB:……………………………. WBC:……………………….. ESR:………… ……. 
   Poly:………………………….. Lymph:…………………….. Esino:……………………...  
   Mono:………………………Platelets:………………………. Film:…………… …… 
L.F.T. & Enzgmes: 
    T. Protein:………………………… ALB:………………… BIL:…………………………… 
    AlK:……………………S  Got:……………………….SGPT:………………………………. 
Blood Urea:………………………….. NA:….…….……………. K:…………… ……… 
Others:………………………………………………………………………………………… 
RADIOLOGY: 
X-Ray: 
Normal:…………………………………. Soft tissue mass:……………………………….. 
Periosteal Reaction:…………………………… Destruction :…………………………… 
Ultrasound :…………………………………… …………………………………… 
……………………………………………………………………………………………. 
HISTOPATHOLOGY : 
Slide No:………………………………………….. 
Hospital:………………………………….. 
Grain :…………………………… ……………………………………………………… 
Tissue Reaction:……………………………… ………………………………………………. 
Others :………………………………………… ………………………………………. 
CYTOLOGY: …………………………………………………………………….. 
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TREATMENT: 
Medical treatment: 
Date:…………………………………  Drugs:……………………………………. 
Surgery: 
Date:……………………………. Indications:…………………………….. 
Anaesthesia:……………………………………………………………………. 
Excision:……………………………… Bone Curettage:…………….. 
Debulking:………………………………………………. Dressing: ……………….. 
Complications:…………………………………………………………………………….. 
Follow-up :…………………………………………………………………………………… 
…………………………………………………………………………………………………… 
…………………………………………………………………………………………………… 
…………………………………………………………………………………………………… 
…………………………………………………………………………………………………… 
 
